Long term results of accelerated hypofractionated chemoradiation in oropharyngeal cancer
Andrew Hartley,
United Kingdom
PO-0187
Abstract
Long term results of accelerated hypofractionated chemoradiation in oropharyngeal cancer
Authors: Margriet Vreugdenhil1, Helen Benghiat1, Tom Beech2, Ian Boon3, Cheng Boon4, John Glaholm5, Paul Sanghera1, Andrew Hartley1
1Queen Elizabeth Hospital, Hall-Edwards Radiotherapy Research Group, Birmingham, United Kingdom; 2Queen Elizabeth Hospital, E.N.T., Birmingham, United Kingdom; 3St James' Hospital, Leeds Cancer Centre, Leeds, United Kingdom; 4New Cross Hospital, Deansley Centre, Wolverhampton, United Kingdom; 5Royal Marsden Hospital, Clinical Oncology, London, United Kingdom
Show Affiliations
Hide Affiliations
Purpose or Objective
The COVID 19 pandemic has prompted a re-examination of hypofractionation in head and neck cancer.
Material and Methods
A previously reported cohort of 85 patients treated at a single centre with hypofractionated accelerated intensity modulated radiotherapy and synchronous carboplatin or cetuximab between June 2009 and May 2012 for oropharyngeal squamous cell carcinoma was retrospectively re-examined.
Results
7 year Overall Survival (OS) was 63% (95% confidence intervals (52-72%)) with freedom from locoregional recurrence of 79% (68-86%). Patients with p16 positive disease had a significantly better OS in comparison with p16 negative patients (p<0.005) (7 year OS 72% vs. 42%). Patients treated with synchronous carboplatin had superior survival compared with patients treated with synchronous cetuximab (p<0.005) (7 year OS 74% vs. 19%). Incidence of second malignancy and osteoradionecrosis at 7 years was 11 % (5-22%) and 11% (5-23%) respectively.
Conclusion
This study provides data on long terms outcomes for 4 week accelerated hypofractionated intensity modulated chemo radiation and suggests that a platinum based 4 week combination might be considered when there is extreme pressure on radiotherapy resource.